|
2019
|
Invention
|
Combination therapy for inducing immune response to disease.
The present invention concerns comp... |
|
2018
|
Invention
|
Murine, chimeric, humanized or human anti-tnf-alpha antibodies. The present invention concerns co... |
|
2017
|
Invention
|
Disease therapy by inducing immune response to trop-2 expressing cells. + cancer cells. The cytot... |
|
|
Invention
|
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors.
The p... |
|
|
Invention
|
Combination therapy for inducing immune response to disease. + cancer cells. The cytotoxic immune... |
|
|
Invention
|
Murine, chimeric, humanized or human anti-il-6 antibodies. The present invention concerns composi... |
|
|
Invention
|
Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors. The ... |
|
|
Invention
|
T-cell redirecting bispecific antibodies for treatment of disease. The present invention concerns... |
|
|
Invention
|
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-loc... |
|
2016
|
Invention
|
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of... |
|
|
Invention
|
Dock-and-lock (dnl) complexes for therapeutic and diagnostic use.
Disclosed herein are methods a... |
|
|
Invention
|
Tetrameric cytokines with improved biological activity. The present invention concerns methods an... |
|
|
Invention
|
Combination therapy for inducing immune response to disease. The present invention concerns combi... |
|
|
Invention
|
Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic... |
|
|
Invention
|
Pegylation by the dock and lock (dnl) technique. The present invention concerns methods and compo... |
|
|
Invention
|
Dock-and-lock (dnl) vaccines for cancer therapy.
The present invention concerns methods and comp... |
|
|
Invention
|
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy.
The present... |
|
|
Invention
|
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoi... |
|
|
Invention
|
Immunoconjugates with an intracellularly-cleavable linkage. The invention relates to therapeutic ... |
|
|
Invention
|
Combination therapy with anti-cd74 and anti-cd20 antibodies provides enhanced toxicity to b-cell ... |
|
|
Invention
|
T-cell redirecting bispecific antibodies for treatment of disease.
The present invention concern... |
|
|
Invention
|
Interferon lambda-antibody complexes. The present invention concerns methods and compositions for... |
|
2015
|
Invention
|
Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy. The present invent... |
|
|
Invention
|
Methods and compositions for generating bioactive assemblies of increased complexity and uses.
T... |
|
|
Invention
|
Disease therapy by inducing immune response to trop-2 expressing cells. The present invention con... |
|
2014
|
Invention
|
Bispecific antibodies that neutralize both tnf-α and il-6: novel therapeutic agent for autoimmune... |
|
|
Invention
|
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoim... |
|
|
Invention
|
Stably tethered structures of defined compositions with multiple functions or binding specificiti... |
|
|
Invention
|
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors. The pr... |
|
|
Invention
|
Dock-and-lock (dnl) complexes for therapeutic and diagnostic use. Disclosed herein are methods an... |
|
|
Invention
|
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enh... |
|
|
Invention
|
Methods and compositions for generating bioactive assemblies of increased complexity and uses. Th... |
|
2013
|
Invention
|
Novel strategies for improved cancer vaccines.
The present invention concerns methods and compos... |
|
|
Invention
|
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimm... |
|
|
Invention
|
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy. The present ... |
